Month: September 2025

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that, during August 2025, the Company repurchased 460,000 Ordinary Shares at an average price of $9.82. As of August 31, 2025, Nexxen had 57,657,924 Ordinary Shares outstanding (excluding treasury shares) and approximately $2.7 million remaining under its current share repurchase program authorization. As announced on August 15, 2025, Nexxen intends to initiate a new $20 million Ordinary Share repurchase program, which would commence following the completion of its current program. The Company will provide an update upon initiation of the new repurchase program or in the event of any delay related to creditor...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately. “We’re thrilled to welcome Misbah as Maze’s Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026,” said Jason Coloma, Ph.D., chief executive officer of Maze. “Misbah’s proven track record in scaling biotech companies, combined with deep financial and operational...

TORONTO, Sept. 02, 2025 (GLOBE NEWSWIRE) — Forsys Metals Corp. (TSX: FSY) (FSE: F2T) (NSX: FSY) (“Forsys” or the “Company”) Forsys is pleased to announce further drilling results from its ongoing extension and exploration drilling program at the Valencia deposit (under ML 149), part of the Company’s Norasa Uranium project (“Norasa1”). A further 115 boreholes totalling 11,739 metres (“m”) have been drilled since results were previously reported on February 26, 2025. The Company has received 10,832 metres of processed downhole gamma survey results. The mineralised intercepts are reported and presented in Table 1 below. Uranium intercepts have been logged, both in the infill drilling and in the resource extension drilling patterns, within the Valencia Main pit shell volume, reporting new uranium mineralization and encouraging infill...

Dublin, Ireland, Sept. 02, 2025 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), today announced that its subsidiary, Bright Hydrogen Solutions Ltd (“BrightHy Solutions”), has been selected to advance to final contract negotiations as part of two tender processes to develop two new green hydrogen projects in southern Europe. BrightHy Solutions was selected as the preferred partner to advance to the negotiations of the final contract for the development of a 2 MW hydrogen project for a cement company in southern Europe, aimed at supplying both hydrogen and oxygen as part of the client’s decarbonization objectives. This project would be the first project in the Company’s proposed hydrogen investment partnership structure, in which the Company would receive a €30 million commitment under terms...

Turnkey platform offers banks and credit unions cannabis deposits with lower overhead and workload, reduced regulatory and operational risks and no reputational exposure DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (Safe Harbor or the “Company”) (Nasdaq: SHFS), a fintech leader in providing financial services and credit facilities to the regulated cannabis industry, announced the official launch of its Fully Managed Cannabis Banking Program, the industry’s first and only solution offering complete operational and compliance outsourcing for financial institutions. The announcement comes ahead of CEO Terry Mendez’s participation in the PBC Conference 2025, where he will join industry leaders to discuss the future of cannabis banking, reinforcing the Company’s commitment to delivering compliant,...

VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) —  Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that, further to the Company’s news release dated October 3, 2024, it intends to proceed with the consolidation (the “Consolidation”) of its issued and outstanding common shares (“Shares”) on the basis of five (5) pre-Consolidation Shares for every one (1) post-Consolidation Share. “Consolidation of the Company Shares should result in a price environment that allows for immediate marginability, the opportunity of greater blue-sky potential in the US and foreign markets, increased sophisticated investor interest and greater opportunity for inclusion in various indexes and/or index funds. In addition, few of the Company’s peer groups are margin eligible, providing...

Dual recognition showcases eMaint’s depth across both maintenance execution and enterprise asset strategyeMaint Named a Leader in the Verdantix Green Quadrant for CMMS – One of Only Two Vendors Also Recognized for EAMeMaint Named a Leader in the Verdantix Green Quadrant for CMMSNorwich, UK, Sept. 02, 2025 (GLOBE NEWSWIRE) — Tuesday 2nd September, Norwich, UK – eMaint, which empowers reliability and maintenance teams with the Enterprise Asset Management software needed to optimize asset performance, today announced that it has been positioned as a Leader in the 2025 Verdantix Green Quadrant for Computerized Maintenance Management Systems (CMMS). This recognition follows eMaint’s Leader placement in the 2025 Verdantix Green Quadrant for Enterprise Asset Management (EAM), making it one of only two companies to be named...

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for patient-friendly subcutaneous dosing every eight weeks or longer Interim, biomarker-rich Phase 1 healthy volunteer data are expected in the first half of 2026, and are anticipated to define dose and dosing interval selection based on biomarker responses associated with optimal clinical activity in IgAN patientsSAN FRANCISCO and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced...